Abstract: A startup circuit initializes a voltage of a capacitor of a switch-capacitor regulator. The startup circuit includes a voltage forming circuit and a control unit. The voltage forming circuit selectively electrically connected to the top and the bottom of the capacitor. In a first operation phase, the voltage forming circuit is electrically connected to the top and bottom of the capacitor, and the top and bottom of the capacitor are connected to each other, and the voltages of the top and bottom are set as a preset high voltage. In a second operation phase, the voltage forming circuit disconnects the top and the bottom, and generates current flowing out from the bottom of the capacitor until the voltage cross the capacitor is equal to the preset initial voltage. In the third operation phase, the startup circuit is disconnected from the capacitor.

Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.

Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Abstract: A digital regulator system is provided. The digital regulator system includes a digital regulator circuit and a compensation circuit. The digital regulator circuit outputs an output current and an output voltage. The digital regulator circuit adjust the output current by decreasing or increasing a unit current according to at least a reference voltage and a feedback voltage. The compensation circuit receives the output voltage as well as decreases or increases a unit voltage of the output voltage to generate and output the feedback voltage according to the variation of the output current.

Abstract: A zero current detection system for a switching regulator is provided. The switching includes an inductor. In the zero current detection system, a comparator has a positive input coupled to a terminal of the inductor and an output terminal for outputting a comparison result signal; a first signal latch circuit has a clock terminal for receiving the comparison result signal and outputting a latched output signal; a delay line module starts counting upon receipt of the latched output signal, and then outputs a zero current detection signal after counting a delay time; in response to the zero current detection signal, a voltage sampling module samples a node voltage at two different time points, to generate two sampling voltages; a delay control module adjusts the delay time of the delay line module according to the two sampling voltages.

Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Abstract: A power converter includes a switched-capacitor conversion circuit and an inductor buck circuit. The switched-capacitor conversion circuit receives an input voltage, and is operated, according to the first switching frequency, to convert the input voltage into an intermediate voltage. The inductor buck circuit and the switched-capacitor conversion circuit are connected in series. The inductor buck circuit receives the intermediate voltage, and generates an output voltage on a conversion output terminal thereof according to the intermediate voltage. The minimum value of the first switching frequency is determined by the intermediate voltage.

Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.

Abstract: A voltage regulation system, a regulator chip and a voltage regulation control method thereof are provided. The voltage regulation control method includes the steps of disabling a first regulator, and electrically connecting an input terminal of a second regulator to a power supply terminal; setting a voltage on a second terminal of a first transistor of the first regulator to a ground voltage for a predetermined period; next, turning off the first transistor and the second transistor of the first regulator; next, activating the second regulator, and detecting the voltage on the second terminal of the first transistor; when the voltage on the second terminal of the first transistor is equal to the voltage on the power supply terminal, determining that an inductor electrically connected between the first regulator and the second regulator; otherwise, determining that first regulator and the second regulator are not electrically connected to each other.

Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.

Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.

Abstract: A control system of a switching voltage regulator includes an adjustable switched-capacitor conversion circuit, an error generator, and a controlling module. The adjustable switched-capacitor conversion circuit has a plurality of discrete conversion rates, and selects a corresponding conversion rate and outputs an output voltage according to a signal of the conversion rate. An error generator is connected to the adjustable switched-capacitor conversion circuit and compares the output voltage with an external reference voltage to obtain an error voltage. The controlling module is connected between the error generator and the adjustable switched-capacitor conversion circuit to store a plurality of control variable sets, and selects one of plurality of control variable sets according to the error voltage. Afterwards, the controlling module calculates to output the signal of the conversion rate and further adjust the output voltage according to the selected control variable sets.

Abstract: A digital control system for voltage regulation and a method thereof are disclosed. The digital control system includes an adjustable voltage regulation circuit having multiple discrete conversion ratios, an error generator, a digital controller and a conversion ratio controller. The adjustable voltage regulation circuit, the error generator, the digital controller and the conversion ratio controller form a closed loop control system. The adjustable voltage regulation circuit includes a conversion ratio controlling terminal receiving a conversion ratio signal. The error generator compares an output voltage of the adjustable voltage regulation circuit with a reference voltage to generate an error voltage, and the digital controller outputs a digital control signal to the conversion ratio controller according to the error voltage.

Abstract: A voltage regulation system, a regulator chip and a voltage regulation control method thereof are provided. The voltage regulation control method includes the steps of disabling a first regulator, and electrically connecting an input terminal of a second regulator to a power supply terminal; setting a voltage on a second terminal of a first transistor of the first regulator to a ground voltage for a predetermined period; next, turning off the first transistor and the second transistor of the first regulator; next, activating the second regulator, and detecting the voltage on the second terminal of the first transistor; when the voltage on the second terminal of the first transistor is equal to the voltage on the power supply terminal, determining that an inductor electrically connected between the first regulator and the second regulator; otherwise, determining that first regulator and the second regulator are not electrically connected to each other.

Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Abstract: A DC-DC power converter circuit includes a switched-capacitor circuit, an error amplifier, a latched comparator and a switching controller. The error amplifier adjusts an error amplification signal of the error amplifier in response to an output voltage of the switched-capacitor circuit and a reference voltage. The error amplification signal is then fed to the latched comparator as a comparison reference, resulting in the DC-DC power converter circuit being able to more precisely maintain the output voltage within a predetermined range.

Abstract: Illustrated are a switched-capacitor DC-DC convertor and a control method thereof. The switched-capacitor DC-DC convertor includes a switched-capacitor circuit, a latched comparator and a clock generating module. The switched-capacitor circuit converts an input voltage into an output voltage through a phase switching operation. The latched comparator receives a clock signal, and compares the output voltage and a reference voltage according to the clock signal, to generate the control signal, which triggers a phase switching operation of the switched-capacitor circuit. The clock generating module generates the clock signal, and adjusts a frequency of the clock signal according to variation of the control signal.

Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.